Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
Binds the myristoyl pocket of the ABL1 kinase domain (STAMP mechanism), allosterically inhibiting BCR::ABL1 kinase activity, including activity of many mutant forms. It acts at a site distinct from the ATP-binding pocket targeted by conventional tyrosine kinase inhibitors.
Indications / reported uses
Treatment of Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase (Ph+ CML-CP) in adults with product-specific prior-treatment or mutation criteria; consult current US and EMA product information for exact lines of therapy
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Asciminib PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Asciminib Permitted Daily Exposure (PDE) report (the Asciminib PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Asciminib Occupational Exposure Limit (OEL) report (the Asciminib OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.